Ting Zhang

US Patent:

20180153894, Jun 7, 2018

Filed:

Jun 24, 2016

Appl. No.:

15/737683

Inventors:

- Boston MA, US
Ting Zhang - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

A61K 31/519
A61K 31/437
A61K 31/34
A61K 31/381
A61K 31/166
A61K 31/167
A61K 45/06
C07D 491/048
C07D 495/04
C07D 519/00

Abstract:

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g., PI5P4Kα, PI5P4Kβ, or PI5P4Kγ)) in the subject.